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9SUMMARY
This study was focused on determining the genetic background of Megaloblastic Anemia 1
(MGA1), also known as the Gräsbeck-Imerslund disease. MGA1 is an autosomal recessive
disorder that belongs to the Finnish disease heritage. The disease is characterized by juvenile
megaloblastic anemia, failure to thrive and neurological symptoms due to selective intestinal
malabsorption of vitamin B12. The disease was originally described by Ralph Gräsbeck and
collaborators in Finland and Olga Imerslund in Norway about 40 years ago and the majority
of the Finnish and the Norwegian patients were identified during the following years. Since
the early 1980’s almost no new cases occurred in the two populations, leading to doubts
concerning a Mendelian inheritance for the condition. The disease has generally been thought
to be due to an error in the intrinsic factor receptor (IF-R) in the distal small intestine. For the
present study patients with megaloblastic anemia due to cobalamin deficiency that fulfilled
the diagnostic criteria were collected from both Finland and Norway. The patients from
Finland were identified by perusing the hospital records.
Using six multiplex Finnish families the locus for MGA1 was mapped with linkage analysis
to a 6-cM region on the short arm of chromosome 10. The linkage was confirmed with three
Norwegian multiplex families and 11 additional Finnish families. Use of linkage
disequilibrium (LD) and haplotype analysis in the Finnish families further narrowed the
critical region to ~2 cM. A YAC contig was constructed over a distance of approximately 4
cM to positionally clone the MGA1 gene. Simultaneously, the obvious candidate gene for
MGA1, the receptor for the intrinsic factor (IF)-B12 complex was identified by a functional
approach by a Danish-French research team. The protein was named cubilin and the gene
designated CUBN. CUBN was mapped to the same chromosomal region, by fluorescence in
situ hybridization (FISH), radiation hybrid (RH) mapping and screening of YAC clones, as
previously identified by linkage analysis in the Finnish and Norwegian MGA1 families.
Screening of our YAC contig with CUBN intragenic markers further confirmed the gene as a
functional positional candidate gene for MGA1.
The cubilin gene CUBN was screened for mutations in Finnish and Norwegian MGA1
families. Two mutations were identified in the Finnish population. The first Finnish mutation
(FM1), found in the majority of the Finnish patients, was a 3916C->T missense mutation in
CUB domain 8 changing proline to leucine (P1297L). The second mutation (FM2), seen in
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only one affected, was a point mutation activating a cryptic splice site that results in the in
frame insertion of multiple stop codons in the CUB domain 6 intron. No mutations have been
identified in the Norwegian patients.
The genomic structure of the 36-domain cubilin protein was determined by LR-PCR and
direct sequencing of our BAC contig covering the entire ~170 kb gene. A total of 67 exons
and 66 introns were identified in addition to the putative promoter region.
The IF-R is expressed in the ileum and the kidney tubules and is found in urine. The urinary
activity of the IF-R was measured in some of the Finnish MGA1 patients by using radioactive
vitamin B12 (57Co) cyanocobalamin (CNCbl) bound to intrinsic factor (IF) as a ligand. A
markedly decreased and nearly undetectable binding activity of the IF-vitamin B12 complex
was observed in the patients compared with their healthy relatives and the controls. The assay
can therefore be used for initial diagnostic purposes. The characterization of the cubilin gene
and the mutations responsible for MGA1 will in the future facilitate more exact diagnosis of
new suspected cases at an earlier stage of the disease, which is important for an appropriate
treatment.
11
1. INTRODUCTION
Megaloblastic anemias in children are mainly due to folate or vitamin B12 (cobalamin)
deficiency (Chanarin 1987). Cobalamin (Cbl) deficiency is the most common cause of
megaloblastic anemia in the Nordic countries while megaloblastic anemia due to folate
deficiency is relatively rare (Gräsbeck 1984, Gräsbeck & Weber 1997). Megaloblastic anemia
with neurological disturbances, recurrent infections, developmental delays and failure to
thrive are characteristic symptoms of vitamin B12 deficiency in infancy (Visakorpi &
Furuhjelm 1967, Campbell et al. 1981, Wulffraat et al. 1994). Megaloblastic anemia is a
severe clinical condition that can be fatal if untreated.
All presently known inherited disorders in human cobalamin metabolism are single gene
defects, inherited as autosomal recessive traits that can give rise to mental retardation and
other severe neurological consequences (Linnell & Bhatt 1995). They affect either the
absorption of cobalamin from the intestine, their transport in the blood or their intracellular
metabolism. There are several different defects, including impaired function or expression of
intrinsic factor (IF), the intrinsic factor receptor (IF-R), transcobalamin II (TC II) or the
various reductases and synthases required for synthesis of adenosylcobalamin (AdoCbl) and
methylcobalamin (MeCbl) (Linnell & Bhatt 1995).
Hereditary forms of vitamin B12 deficiency resulting in megaloblastic anemia are known to
relate to low or absent secretion of intrinsic factor (IF) (Pernicious anemia, MIM 261000)
(McNichol & Egan 1968, Katz et al. 1972), to decreased or absent synthesis of functional
transcobalamin II (TC II deficiency, MIM 275350) (Hakami et al. 1971, Hitzig et al. 1974,
Burman et al. 1979) or to a defect in the intestinal epithelium leading to decreased uptake of
the IF-vitamin B12 complex and therefore to vitamin B12 deficiency (Gräsbeck-Imerslund
disease, Megaloblastic anemia 1 (MGA1, MIM 261100) (Gräsbeck et al. 1960, Imerslund
1959, 1960).
At the time when this study was initiated, more than thirty years had elapsed since MGA1 was
first independently described by Ralph Gräsbeck and co-workers in Finland (Gräsbeck et al.
1960) and Olga Imerslund in Norway (Imerslund 1959, 1960).
The goal of this study was to prove the existence of MGA1, its autosomal recessive mode of
inheritance and define the gene responsible for MGA1.
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2. REVIEW OF THE LITERATURE
2.1. Megaloblastic anemia
Megaloblastic anemia is a hematologic disorder characterized by the production in the bone
marrow and increase in the peripheral blood of abnormally large nucleated cells, including
immature erythrocytes, superlobulated polymorphic leukocytes and large platelets. There is
usually a reduction in the total white cell and the red cell counts, and sometimes very low
values are seen. Examination of the bone marrow is of great diagnostic importance, since in
cobalamin deficiency megaloblasts are found, hence the name megaloblastic anemia. The
condition is usually due to a deficiency of folate or vitamin B12. In these conditions, cells of
other tissues, especially rapidly replicating, e.g. epithelial cells are also affected and the
corresponding histology altered (Gräsbeck & Salonen 1976, Chanarin 1979). The best know
condition is pernicious anemia caused by vitamin B12 deficiency resulting from lack of
secretion of gastric intrinsic factor (IF). This, in turn, is usually due to atrophy of the gastric
mucosa caused by an autoimmune process (Chanarin 1979).
Although the clinical symptoms for the different types of congenital megaloblastic anemia are
similar, there is a major clinical difference in the age of onset. While neither one of the two
congenital Cbl transport protein deficiencies, the more frequently occurring pernicious anemia
or MGA1, manifests itself before the age of one year, most TC II deficient patients develop
severe megaloblastic anemia as early as 1 to 3 months after birth (Gräsbeck & Salonen 1976,
Burman et al. 1979, Hall 1992). In infants with congenital vitamin B12 malabsorption,
megaloblastic anemia generally develops later between 12-18 months by which time the
stored cobalamin received from the mother during the pregnancy is exhausted (Furuhjelm &
Nevanlinna 1973, Linnell & Bhatt 1995).
Absorption tests using radioactive labeled vitamin B12, are useful techniques to determine
vitamin B12 malabsorption even when there are no signs of vitamin B12 deficiency
(Gräsbeck et al. 1956). The usual technique, Schilling’s urinary excretion test, measures how
much of the orally ingested radioactively labeled vitamin B12 is excreted in the urine
following a flushing dose of intramuscular injected non-radioactive vitamin B12. It has been
shown to be a useful measure of intestinal cobalamin absorption (Schilling 1953).
13
Another rare cause of megaloblastic anemia, previously more common in the eastern parts of
Finland, where also MGA1 occurred more frequently, was fish tapeworm Diphyllobothrium
latum infection (Nyberg et al. 1958, Gräsbeck et al. 1962). It was shown that D. latum impairs
vitamin B12 absorption in its host and therefore frequently causes hematologic changes from
mild macrocytosis to megaloblastic anemia. Tapeworm anemia very much resembles
megaloblastic anemia caused by congenital selective vitamin B12 malabsorption (MGA1). It
also occurred among very young children. Therefore it was of great importance to exclude the
existence of D. latum in patients suffering from megaloblastic anemia (Nyberg et al. 1958,
Gräsbeck et al. 1962, von Bonsdorff 1977). Today tapeworm anemia is very rare in Finland
primarily as a result of changes in dietary habits, food preparation and population hygiene
(Gräsbeck & Weber 1997).
2.1.1.   Megaloblastic anemia 1 (MGA1)
Megaloblastic anemia 1, originally named Gräsbeck-Imerslund disease or Imerslund-
Gräsbeck disease or syndrome, is a specific vitamin B12 malabsorption defect that is
relatively easy to recognize on the basis of the frequent association of megaloblastic anemia
and a benign proteinuria (Gräsbeck et al. 1960, Imerslund 1959, 1960). In the Gräsbeck-
Imerslund disease the clinical signs are similar to those in juvenile pernicious anemia (lack of
IF secretion), but the cause is defective uptake of the intrinsic factor-vitamin B12 (IF-B12)
complex in the terminal ileum instead of impaired IF secretion (Gräsbeck 1972). The presence
of proteinuria may indicate that the receptor facilitating IF-B12 uptake in the intestine is also
important for kidney function (Gräsbeck 1997, Moestrup et al. 1998).
A recessively inherited form of megaloblastic anemia has also been detected in a family of
giant schnauzer dogs. These dogs also have megaloblastic anemia as a result of selective
vitamin B12 malabsorption and their phenotype greatly resembles MGA1 (Fyfe et al. 1989,
1991a).
The disease may escape attention since the first symptoms tend to be very unspecific, such as
recurrent infections and failure to thrive (Gräsbeck & Kvist 1967). The disease is however
usually diagnosed during the first 2-5 years of life. The diagnosis is based on clinical findings
such as hematological tests revealing typical anemia, developmental delay and neurological
lesions. The therapy is lifelong and consists of intramuscular injections of vitamin B12. When
properly treated the disease is a fairly innocuous condition.
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In megaloblastic anemia, hemoglobin decrease is usually less marked because of the increased
size of the red cells leading to increased total hemoglobin content per cell. This results in a
poor correlation between the cobalamin and the hemoglobin concentrations, making a
hemoglobin determination alone an unreliable method in the diagnosis and therapy of
cobalamin deficiency states. Since poor absorption of vitamin B12 is the usual cause of
megaloblastic anemia, the serum cobalamin (Cbl) concentration is determined and Schilling
absorption tests I (with Cbl only) and II (with IF-Cbl) are performed (Gräsbeck et al. 1960,
Gräsbeck et al. 1962, Gräsbeck & Salonen 1976, Nexø et al. 1994, Linnell & Bhatt 1995).
2.1.2.   The IF-receptor, a candidate gene for MGA1
Since the molecular background of the Gräsbeck-Imerslund disease has not been known there
have been different hypotheses and speculations about the biochemical defect(s) underlying
the disease. The most widely accepted theory, already suggested by Gräsbeck and co-workers
(Gräsbeck et al. 1960), has been an abnormality or lack of the receptor for IF-B12 complex in
the ileum. Lack of IF-receptor binding activity in the ileum has been demonstrated in the
patients (Seetharam et al. 1981, Burman et al. 1985). A defective brush-border expression of
the IF-receptor in the ileum has also been observed in the giant schnauzer dogs with the
inherited intestinal malabsorption of vitamin B12 (Fyfe et al. 1991b). However, in other
reported cases there seem to be no defect in the ileal receptors for the IF-B12 complex.
Instead the defect may be in another of the links in the chain of reactions transferring
cobalamin from the receptors in the ileum to transcobalamin II (TCII), which transports
vitamin B12 in the blood (MacKenzie et al. 1972).
2.1.3. Vitamin B12
Vitamin B12 was first isolated as cyanocobalamin (CNCbl) in 1948 (Rickes et al. 1948, Smith
& Parker 1948). It belongs to the corrin compounds, which are characterized by a corrin ring
containing a central cobalt (Co) atom and various axial ligands (Gräsbeck & Salonen 1976).
Cobalamin, vitamin B12, is synthesized by bacteria and other microorganisms growing in soil
and water and in the rumen or intestine of e.g. sheep and cattle (Allen 1975, Gräsbeck &
Salonen 1976). Cobalamins are essential vitamins, which end up in higher animals via food
chains. In man the cobalamins are obligatory nutrients. Rich dietary sources of cobalamin are
liver, kidney, meat, seafood and dairy products (Faquharson & Adams 1976, Gräsbeck &
Salonen 1976, Sandberg et al. 1981). The cobalamins play an important role in several
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intracellular reactions in mammals, such as in the metabolism of e.g. protein, fats and
carbohydrates, in blood formation and in neural functions (Gräsbeck & Nyberg 1957, Hansen
& Nexø 1987). Vitamin B12 is needed for the synthesis of DNA, i.e. for supplying the methyl
group to thymine. In vitamin B12 deficiency RNA and protein synthesis are not affected but
DNA replication is, which results in large cells that do not divide (Gräsbeck & Salonen 1976).
Figure 1.
The chemical structure of cobalamin. (From Fenton & Rosenberg 1978)
The intestinal absorption of vitamin B12 depends on its binding to specific transport proteins
(Neale 1990). Cobalamin liberated by digestion is first bound to R-protein or haptocorrin
(HC) (also called cobalophilin) contained in saliva, other secretions and leukocytes.
Pancreatic enzymes break the complex and the vitamin is bound to intrinsic factor (IF), a
protein secreted by the gastric mucosa. The IF-B12 complex is transported to the distal small
intestine, where it attaches to the receptors on the enterocyte. For the attachment calcium ions
and neutral pH are needed. Following the absorption of the IF-B12 complex to the ileal
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receptor, according to the current view, the whole complex is internalized after which IF-B12
is segregated from the receptor and directed to the lysosomes for degradation of IF and the
receptor is recycled to the membrane. TC II (also called transcobalamin: TC), present in the
blood circulation and in various tissue fluids, is responsible for the essential delivery of
cobalamin to most tissues (Allen 1975, Neale 1990, Linnell & Bhatt 1995). After oral intake
there is a delay of several hours before the vitamin appears in the blood (Doscherholmen et al.
1957, Birn et al. 1997).
When there is an acute requirement for various metabolic functions in man there are large
cobalamin stores available in liver and smaller ones in kidney, gut, lung endocrine glands and
skeletal muscle. In cobalamin disorders all dividing cells in the body are affected although
tissues with rapid cell formation such as bone marrow, blood and epithelia show the strongest
signs (Gräsbeck & Salonen 1976, Linnell & Bhatt 1995).
2.2. The Finnish disease heritage
The concept of a “Finnish disease heritage” was introduced by Norio, Nevanlinna and
Perheentupa in 1973 and consisted initially of 10 inherited diseases that were much more
prevalent in Finland than in other populations (Norio et al. 1973). Today that concept includes
some 30 diseases with a wide diversity of clinical phenotypes (de la Chapelle & Wright 1998,
Peltonen et al. 1999) (see Table 1). The majority of the diseases are autosomal recessive with
the exception of two autosomal dominant and two X-chromosomal recessive disorders. On the
other hand, several recessive diseases that are common elsewhere are rare in the Finnish
population, e.g. cystic fibrosis (Norio et al. 1973, Kere et al. 1989, de la Chapelle 1993, de la
Chapelle & Wright 1998). Most disorders of the Finnish disease heritage are rare in the other
Nordic countries. Nevertheless, progressive myoclonus epilepsy (EPM1) or Unverricht-
Lundborg disease is an example of another disease in addition to MGA1 that also has been
found in other Scandinavian countries (Norio 1981). Today the loci for the majority of the
Finnish diseases have been assigned to a specific chromosome and in several cases the
defective gene has been cloned and identified.
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The Finns are a classic example of a genetically isolated population that is thought to descend
mostly from a small number of original founders that existed about 2000 years ago. Due to
linguistic, geographic and religious reasons the Finns have remained highly isolated from
their Nordic and Slavic neighbors. The small isolated founder population that rapidly
increased but with frequent “bottlenecks”, due to wars and severe epidemics and famines,
allowed the founder effect and genetic drift to form the Finnish gene pool (Nevanlinna 1972).
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2.3. Identification of disease genes
There are different strategies for identifying human disease genes depending on how much is
known about the pathogenesis of the disease and availability of already mapped and cloned
putative candidate genes. The identification of disease causing genes can be accomplished
either by functional or positional cloning (Collins 1992, Ballabio 1993). A functional cloning
approach can be applied when the basic biochemical defect of the disease is known (Collins
1992). Both the hemophilia A gene (Gitschier et al. 1984) and the gene for phenylketonuria
(Robson et al. 1982) were identified using this strategy. Another cloning strategy based on a
similar but not that precise functional approach is the position-independent candidate gene
approach. Using this procedure still some functional information about the disease gene is
needed. There has to be a general idea of the molecular pathogenesis of closely related human
or animal disease phenotypes (Collins 1995).
However, for the majority of inherited diseases the knowledge about the molecular
background underlying the disease is usually limited and generally possible candidate genes
have not yet been cloned and characterized. In such cases, mapping the disease gene to a
specific subchromosomal localization by genetic linkage analysis followed by positional
cloning makes cloning of novel genes possible. Pure positional cloning is, however, usually
very time consuming without any factors limiting the critical candidate region, such as a
strong linkage disequilibrium (for example the diastrophic dysplasia (DTD) gene, Hästbacka
et al. 1994), usually only seen in genetically homogenous populations (Jorde 1995, Peltonen
2000), or disease associated visible cytogenetic rearrangements as in the dystrophin gene
(Lindenbaum et al. 1979). Therefore the positional candidate gene approach, combining the
knowledge of map position with the increasingly dense human transcript map, is today the
most appealing and predominant method for cloning human disease genes (Boguski &
Schuler 1995, Collins 1995).
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Figure 2. Schematic presentation of steps involved in identification of disease genes by positional
cloning that starts with linkage analysis and ends up in identification of disease causing mutation(s).
2.3.1.   Linkage and linkage disequilibrium analyses
Linkage analysis is often the first step towards localization and characterization of disease
genes. Furthermore, since most inheritable diseases are known only by their phenotype and no
obvious candidate gene generally exists, linkage analysis is the ultimate way to map novel
disease genes. In order to perform linkage analysis, a sufficient number of multiplex families,
with two or more affected children, have to be included in the study in order to confirm or
exclude linkage. The mode of inheritance for the disease studied should be known. Mapping
genes for hereditary diseases is based on the use of polymorphic markers spanning the
genome, where cosegregation of alleles at the marker loci and a genetic trait in families are
studied.
Linkage is observed when two loci located on the same chromosome are inherited together at
a rate corresponding to the distance between them. The recombination fraction (θ) is used as a
measure of the distance between two loci. Theoretically it ranges from (θ)=0, for loci close to
each other, to (θ)=0.5 for loci far apart. Two loci are considered genetically linked when
(θ)<0.5, i.e. recombination is observed in less than 50% of the meiosis. The likelihood of
genetic linkage between loci is given in logarithm of odds, lod score (Z). At the maximum
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total lod score (Zmax) of +3 or greater, linkage is considered proven while –2 or less is often
evidence against linkage. The genetic distances between markers on a genetic map are given
in centimorgan (cM), where two loci showing 1% recombination are 1 cM apart (Ott 1991,
Terwilliger & Ott 1994).
On the other hand, to be able to identify and clone a specific gene, giving rise to the disorder,
a more precise localization is necessary. Linkage disequilibrium is consequently a powerful
statistical method that allows fine-scale mapping and identification of disease genes
(Terwilliger 1995, Xiong & Guo 1997). Linkage disequilibrium or allelic association is a
nonrandom association of alleles at linked loci and reflects the lack of historical
recombinations between the marker and the disease locus. For disease gene mutations,
disequilibrium can therefore be expected only if the majority of the patients have the same
inherited mutation from a shared ancestor. The older the founder mutation is, the closer the
marker has to be to indicate linkage disequilibrium.
In an isolated population, that originates from a small founder population and where the
expansion of the population has occurred by growth rather than by immigration, the
advantage of linkage disequilibrium in high-resolution mapping of disease genes can be
utilized (de la Chapelle 1993, Peltonen 1997, de la Chapelle & Wright 1998, Peltonen et al.
1999). Identification of the genes for diastrophic dysplasia (Hästbacka et al. 1994), congenital
chloride diarrhea (Höglund et al. 1996) and mulibrey nanism (Avela et al. in press) are good
examples where highly informative linkage disequilibrium data facilitated the identification of
the disease locus (Hästbacka et al. 1992, Höglund et al. 1995, Avela et al. 1997). Construction
of chromosomal maps of genetically linked DNA markers has made almost the entire genome
accessible to linkage studies in families where genetic traits are segregating (White et al.
1989).
2.3.2.   DNA polymorphisms as markers
The initial construction of a genetic linkage map in human was based on the idea of using
polymorphic restriction fragment length polymorphisms (RFLP) as markers (Botstein et al.
1980). The first comprehensive human genetic map was assembled by a combination of
linkage analysis and physical localization of selected clones. Polymorphic loci were arranged
into linkage groups estimated to be able to detect linkage to at least 95% of the human
genome (Donis-Keller et al. 1987). Since the information obtained using RFLP is very
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limited, the new genetic hypervariable minisatellite markers, a variable number of tandem
repeats of short DNA sequence (VNTR), greatly improved linkage studies (Nakamura et al.
1987). The source of polymorphic markers has however increased. The standard tool in
linkage analysis is nowadays the use of microsatellite markers, which are simple short
tandem-repeats (STR). One of the most commonly used microsatellite markers have been the
PCR-typeable (AC)n repeats (Weber & May 1989). The (AC)n dinucleotide repeats are highly
tandemly repeated (~15-30 times) abundant DNA elements that have been found in
eukaryotic genomes examined from yeast to human, indicating a high evolutionary
conservation (Hamada et al. 1982, Weber & May 1989). Genetic linkage maps of the human
genome have been constructed primarily based on these polymorphic (AC)n repeats
(Weissenbach et al. 1992, Gyapay et al. 1994, Dib et al. 1996). A collection of tri- and tetra
nucleotide short tandem repeat polymorphisms (STRP) are an example of other tandemly
repeated polymorphic markers that are similarly used in constructing genome wide human
linkage maps (Sheffield et al. 1995). However, the most common variations in the human
genome are the frequently occurring, widely distributed single base pair differences, called
single nucleotide polymorphisms (SNPs) (Collins et al. 1997, Wang et al. 1998). Although the
SNPs are less informative, with only two alleles, than the other highly informative (AC)n and
STRP markers, they are more abundant in the human genome and have a greater potential for
future automated mapping (Wang et al. 1998). The maps with an ever-increasing number of
genetic markers can be used to map any Mendelian trait, particularly monogenic human
diseases (Gyapay et al. 1994).
2.3.3.   Radiation hybrids
Radiation hybrid (RH) mapping is a very useful tool in refining the genetic localization of
disease genes by physical mapping of linked DNA markers. Human RH maps are generated
by a lethal irradiation of diploid human donor cells that are fused to a non-irradiated recipient
rodent somatic cell line (Cox et al. 1990, Walter et al. 1994). In RH mapping the frequency of
X-ray breakage between two markers is used as a statistical measure of the distance between
markers and their order on the chromosome. Unordered DNA markers can be determined with
a very high resolution. The resolution of RH maps depends on the dose of X-rays used to
generate the hybrids. Hybrids generated with high doses, 8000-10,000 rad of X-rays, are very
useful for ordering nearby DNA markers at a 500-kb level of resolution. The distances
between markers are given in centiRays (cR), which are analogous to cM, where 1 cR
corresponds to 1% breakage between two markers and is dependent on the radiation dose
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(Cox et al. 1990). Hybrid panels with lower resolution have also been generated, which are
more useful in ordering markers further apart (Walter et al. 1994). Since RH mapping is based
on statistical likelihood, the RH map does not necessarily always represent the actual physical
order or distances between markers on the chromosomes (Cox et al. 1990, Jones 1997).
A panel of RHs of the human genome is available and can be used to map polymorphic and
non-polymorphic markers and for integrating already existing genetic and physical maps
(Hudson et al. 1995, Gyapay et al. 1996, Stewart et al. 1997). Using the RH approach any
human DNA sequence, that can be distinguished from rodent DNA background, can be
mapped (Cox 1995). RH maps covering the whole genome are also available for mouse
(McCarthy et al. 1997) and rat (Watanabe et al. 1999), allowing comparison and integration of
maps from different species.
2.3.4.   Physical mapping
The ability to physically localize and identify disease genes is greatly enhanced by integrating
already existing genetic and physical maps. Unidentified Sequence Tagged Sites (STSs) and
Expressed Sequence Tags (ESTs) can be mapped by PCR screening using either RH panels
(Gyapay et al. 1996) or yeast artificial chromosome (YAC) or bacterial artificial chromosome
(BAC) libraries (Hudson et al. 1995, Kim et al. 1996, Cai et al. 1998). A new updated
physical map consisting of more than 40,000 STSs representing about 30,000 unique human
genes was published in 1998 (Deloukas et al. 1998). This new gene map may consist of up to
half of the estimated total number of 60,000-100,000 human genes (Antequera & Bird 1993,
Fields et al. 1994), and is therefore of great help and a powerful tool in positional cloning of
single and also more complex disease genes. The initial step in hunting for and identification
of disease genes is the construction of a contig consisting of a set of physically overlapping
cloned DNA fragments spanning the putative region of interest.
The first-generation physical map of the human genome was constructed by screening the
YAC library from CEPH with more than 2,000 polymorphic STS markers distributed over
90% of the genome (Cohen et al. 1993). The physical map was far from complete with poor
coverage for some of the chromosomes. A new updated YAC library was published a few
years later covering about 75% of the human genome in 225 contigs (Chumakov et al. 1995).
Because of their capability to contain large clones up to a megabase or more in size, YACs
have provided a powerful tool for physical mapping and analysis of complex genomes
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(Schlessinger 1990, Dausset et al. 1992). The YACs also played an important role in cloning
of the Huntington disease gene (Zuo et al. 1992, The Huntington’s Disease Collaborative
Research Group 1993). Major disadvantages with using YAC libraries are, however, the
remarkably high frequency of YACs that contain two or more unrelated pieces of DNA
(chimeric YACs) and the instability of some regions (Green et al. 1991). Nevertheless, the
development of the YAC cloning technology has directly enhanced the relationship among
genetic, physical and functional mapping of genomes facilitating the identification of genes
(Larin et al. 1997).
Therefore, for higher resolution physical mapping, overlapping BAC clones have proven to be
more convenient to use than the YACs, mainly due to their smaller clone inserts (in average
around 130-150 kb), clone stability and lower frequency of chimerism. BAC libraries serve to
integrate genetic, STS and cytogenetic map information thus offering an enormous potential
for identification of chromosomal rearrangement, mapping, genomic sequencing and
functional studies (Ashworth et al. 1995, Kim et al. 1996, Cai et al. 1998, Korenberg et al.
1999).
2.3.5. Identification of candidate genes
There are a great variety of different methods for finding and isolating genes in cloned DNA.
A well assembled genomic contig, with no gaps or unrelated sequences, provides a good
starting point for both the search of novel coding sequences and fine mapping of previously
identified candidate genes. Some of the commonly used methods for identifying coding
sequences in cloned DNA are hybridization of the genomic candidate DNA clone against
RNA or mRNA blots (Northern blotting) (Alwine et al. 1977), cDNA libraries (Bonaldo et al.
1994, Lovett 1994) or zoo-blots (Claudio et al. 1994) or the identification and cloning of CpG
islands often associated with the 5’ end of vertebrate genes (Bird 1987, Larsen et al. 1992,
Cross & Bird 1995). Positional transcript mapping using these methods is both difficult and
time consuming. A turning point for disease gene identification has been the Human Genome
Project large-scale sequencing and physical mapping of an ever-increasing number of ESTs,
providing candidate genes for many human genetic diseases (Berry et al. 1995, Schuler et al.
1996, Deloukas et al. 1998).
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The Human Genome Project (HGP) is an international project with the major goal to produce
whole-genome genetic maps, physical maps and a complete ~3,000 megabases (Mb) sequence
map covering all the human chromosomes (Lander 1996, Collins et al. 1998). In the end of
1999 chromosome 22 was the first chromosome to be completely sequenced (Dunham et al.
1999). As early as in the spring of year 2000 at least 90% of the human DNA sequence might
already be ready in a “working draft” form and it is projected that by 2003 the entire human
genome sequence project will be completed (Human Genome Project:
www.ornl.gov/hgmis/hg5yp/). This will tremendously influence the fields of genetics and will
lead to a new understanding of genetic contributions to human diseases (Collins 1999, van
Ommen et al. 1999, Wadman 1999).
2.3.6.   Demonstration of mutations
The ultimate proof that a candidate gene indeed is the disease-causing gene is a demonstration
of mutations in affected individuals. The search for mutations in genes can be very tedious
and expensive (Dean 1995, Forrest et al. 1995). Once a candidate mutation has been observed,
it also must be identified in other patients with the same phenotype. Furthermore, the
mutation should segregate in the affected families according to the mode of inheritance. By
screening a set of healthy unrelated controls from the same population, a sequence change due
to a possible neutral polymorphism may be excluded.
Mutations can be detected e.g. by direct sequencing of the DNA segment (Forrest et al. 1995),
by a gain or loss of a diagnostic restriction site visualized in an agarose gel (Prosser 1993), by
altered banding patterns of single stranded DNA through non-denaturing gels (single strand
conformation polymorphism, SSCP) (Sheffield et al. 1993) or by resolution of heteroduplex
molecules by their instability in denaturing gradient gel electrophoresis (DGGE) (Cariello &
Skopek 1993). After identifying the mutation(s) the question often still remains if the
mutation actually causes the disease. Functional assays may be performed to prove the
connection between the disease phenotype and the mutation(s), provided that the function of
the protein is known (Aittomäki et al. 1995, Forrest et al. 1995).
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2.3.7.   Determination of the gene structure
Gene prediction and the recognition of the exon-intron structure of the coding region, in
addition to the putative corresponding promoter region, has been improved by the
contribution of available computer-assisted nucleotide sequence analysis. The primary
computational approach to eukaryotic promoter recognition was by combining modules
recognizing different individual binding sites in the sequence, and by using some kind of an
overall description of how these sites should be spatially arranged. Because of the large
number of putative transcription binding sites, it has been difficult to identify promoters
correctly based only on the sequence information (Fickett & Hatzigeorgiou 1997, Knudsen
1999, Pedersen et al. 1999, Werner 1999). Since the knowledge of all the mechanisms
involved in transcription, translation and alternative splicing are still far from complete, both
exons and promoter sequences may in spite of all the available new software tools still be
wrongly predicted and partitioned (Pedersen et al. 1999). However, a combinatorial approach
of general promoter prediction with exon-intron predictions may markedly improve the
accuracy of promoter recognition (Werner 1999). Successful and reliable computational
analyzing programs for promoter recognition would also be useful in analyzing the sequence
results from the Human Genome Project (Knudsen 1999).
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3. AIMS OF THE STUDY
The principal purpose of this study was to:
1) To identify and collect patients from Finland and Norway, perform genealogical studies of
the Finnish patients and to map the MGA1 gene with linkage analysis
2) To refine the localization of the gene by fine genetic mapping and physical mapping
3) To characterize the mutations in the MGA1 patients
4) To determine the genomic structure of the cubilin gene
5) To use an urinary radioisotope-binding assay to diagnose MGA1 patients
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4. PATIENTS AND METHODS
4.1. Identification of patients
The majority of the Finnish MGA1 patients were diagnosed in the 1960’s and are not
currently under regular care by a physician. Because of the lack of a main responsible
physician, the primary screening for patients included in this study was based on the study of
hospital records from the 1940’s to today. Nearly all children with severe megaloblastic
anemia in Finland have customarily been referred to the Children’s Hospital of the Helsinki
University Central Hospital. Due to this almost all the MGA1 patients were found in the
records of this hospital. Only sporadic new cases were identified via the National Social
Insurance Institution (KELA-FPA). In Finland all individuals receiving vitamin B12 treatment
orally or as parenteral injections are listed in the records of the Social Insurance Institution
since the cost of the treatment is partly supported by them. The search for potential MGA1
patients was limited to the initiation of vitamin B12 treatment before the age of 15.
All the Norwegian patients participating in this study were originally diagnosed by Dr. Olga
Imerslund in the 1950’s (Imerslund, 1959, 1960), and the blood samples for this study were
collected by Dr. Harald Broch. The clinical pictures of different types of megaloblastic
anemia are very similar and it is consequently difficult to distinguish them from each other.
Therefore the following selection criteria were used to identify possible MGA1 patients from
other patients suffering from megaloblastic anemia (Gräsbeck et al. 1960, Imerslund &
Bjørnstad 1963, Anttila & Salmi 1967, Broch et al. 1984):
1. Appearance of megaloblastic anemia within the first 5 years of life
2. Low serum vitamin B12 levels with good hematologic response to parenteral injections
of vitamin B12
3. Serum folate not decreased
4. Schilling tests I and II showing malabsorption of labeled vitamin B12 even after the
addition of exogenous intrinsic factor (IF)
5. Unhampered absorption of other nutrients when vitamin B12 stores are replenished
(vitamin B12 deficiency causes secondary malabsorption)
6. Exclusion of severe malnutrition or a general malabsorption syndrome
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7. Exclusion of fish tapeworm Diphyllobothrium latum infection
Professor Ralph Gräsbeck kindly scrutinized the patient data and in uncertain cases decided
whether the diagnosis was acceptable or not. A total of 24 Finnish MGA1 patients in 17
families were chosen for this study. Altogether 33 potential Finnish MGA1 patients, in 24
families, were identified of which 27 patients in 19 families fulfilled the study criteria above.
One of the patients lived abroad and was therefore not taking part in this study, while two
other patients had recently died. Following a signed informed consent from the patients,
parents and healthy siblings, venous blood and urine samples were collected from
participating individuals. The study was approved by the Ethical Review Committee of the
Department of Medical Genetics, University of Helsinki and the Finnish National Research
and Development Centre for Welfare and Health, Ministry of Social Affairs and Health
(STAKES).
4.2. MGA1 families and control individuals
A total of nine multiplex MGA1 families, six from Finland and three from Norway, with more
than one affected child were included in the initial linkage study. After linkage was found the
panel of individuals studied was expanded to include the rest of the Finnish MGA1 families.
The Finnish and Norwegian pedigrees are shown in Figure 3.
DNA samples from 158 unrelated healthy Finnish individuals were used as controls and 138
of them originated from eastern and south-central Finland, where the disease is more
prevalent. The remaining 20 samples were obtained from the Finnish Red Cross.
30
Figure 3. The pedigrees of the 17 Finnish and the three Norwegian (bottom) families used in linkage
and haplotypes analyses.
4.3. Genealogical studies
A genealogical study was performed for the Finnish MGA1 patients identified for this study
by examining the well established church parish record system. The church records include
detailed information on birthplaces, deaths, marriages and movements for the majority of the
population. The birthplaces for all the Finnish MGA1 patients’ parents and grandparents and
in some cases their great-grandparents could therefore be determined. Based on the
information from these church registers the pedigrees of the Finnish MGA1 families were
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drawn and the geographic distribution of birthplaces for the patients’ grandparents was
shown.
4.4. Molecular genetic studies
4.4.1.   Genotyping
10-30 ml samples of venous blood were collected in EDTA or heparin from each consenting
individual. DNA was extracted directly from blood leukocytes by standard methods. Most of
the markers used in the initial random screening were highly polymorphic (AC)n-repeats from
the Généthon or Mansfield collections (Dib et al. 1996). A combination of two to six markers
located ~ 20 cM apart were co-amplified in each PCR reaction using published protocols
(Weber & May 1989). The α32P dCTP radiolabelled co-amplified PCR fragments were
separeted on 6% polyacrylamide gels and exposed to X-ray films for 1-7 days.
4.4.2.   Linkage and linkage disequilibrium analyses
Linkage analyses were performed by computer programs from the LINKAGE package
(Lathrop et al. 1984). The simulation program SLINK (Ott 1989, Weeks et al. 1990) was used
to define a minimum number of individuals to be studied in the initial screening. Multipoint
analysis was carried out using the program LINKMAP. All results were obtained under the
assumption of autosomal recessive mode of inheritance, complete penetrance, with sex-
average recombination fractions and allele frequencies obtained through the Genome
Database (GDB) (http://www.gdb.org/) (Pearson 1991, Pearson et al. 1992, Cuticchia et al.
1993).
The haplotypes were constructed manually, assuming the least number of possible
recombinations in each family. Allelic excess, the excess of an allele at a marker locus among
the MGA1 chromosomes (Paffected) versus non-MGA1 chromosomes (Pnormal) of parents or
healthy siblings, was calculated according to the following formula:
Pexcess = (Paffected-Pnormal)/(1-Pnormal), where P denotes the allele frequency.
The Pexcess values serve as a measure of the observed linkage disequilibrium.
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4.4.3.   Radiation hybrid analysis
The RH mapping panels Stanford G3 (Cox 1995) and Genebridge 4 (Gyapay et al. 1996) were
used to determine the order of the microsatellite markers closest to the MGA1 locus. The
PCR-amplified DNA was separated using electrophoresis in either a 1.5% agarose gel or in a
6% polyacrylamide gel. DNA was visualized with ethidium bromide or silver staining
(Bassam et al. 1991).
4.4.4.   Yeast artificial chromosomes
Prescreened YACs were obtained from the UK Human Genome Mapping Program Resource
Center (http://hgmp.mrc.ac.uk/). Altogether 15 YACs containing any of the polymorphic
markers D10S1653, D10S1763, D10S1661, D10S1477, D10S1476, D10S504, AFM234zf10,
D10S1714 or D10S548 were initially identified. Total YAC DNA was prepared from colony
purified YACs according to standard procedures (Hoffman & Winston 1987). The YAC
contig, consisting of nine overlapping YACs between markers D10S1653 and D10S548, was
used to determine the order of new STSs, ESTs and the CUBN intragenic markers.
4.4.5.   Bacterial artificial chromosomes
Using the entire CUBN cDNA as a probe, 25 BAC clones were identified by screening the
Roswell Park Cancer Institute (RPCI) human BAC library (http://bacpac.med.buffalo.edu).
The colony purified BAC clones were grown in Luria Bertani (LB) media supplemented with
chloramphenicol. BAC DNA was extracted using a modified version of the Plasmid Midiprep
kit (Qiagen, Germany) protocol. A contig of 16 overlapping BACs spanning the region
between the intragenic markers in the 5’ and 3’ region of the CUBN gene was assembled. The
sizes of six BAC inserts used in direct sequencing were determined by the field inversion gel
electrophoresis (FIGE) mapper system. BAC DNA was digested with the restriction enzymes
NotI and SacII, the fragments were separeted in a 1% pulse field certified agarose gel, stained
with ethidium bromide and visualized by UV fluorescence.
4.4.6.   RNA extraction and cDNA synthesis
Total RNA was isolated from both fresh white blood cells and lymphoblastoid cell lines using
the RNeasy RNA extraction kit or RNA Stat-60 (Chomczynski & Sacchi 1987). First strand
cDNA was reverse transcribed from total cellular RNA using both random hexamer and oligo
(dT) priming.
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4.4.7.   Sequencing and mutation analyses of the CUBN gene
For sequencing the 10.9 kb CUBN cDNA, multiple PCR primers were designed to cover the
entire region in overlapping fragments. Both the 5’ and 3’ primers were tailed with M13-
forward and M13-reverse tails, respectively, enabling sequencing in both directions.
Sequencing was done using the BigDye-Terminator AmpliTaq FS Cycle sequencing kit (PE
Applied Biosystems). The Sequence Navigator software (PE Applied Biosystems) was used
to confirm heterozygous position and to align both directions of the respective ladders (Phelps
et al. 1995). Sequence alterations were examined for restriction-site polymorphisms using the
DNAStar software.
The Finnish mutation FM1 was initially identified by the sequencing of a RT-PCR amplified
cDNA fragment. The screening of the FM1 mutation, C->T, in the rest of the MGA1 families
and the control individuals was performed by direct sequencing of PCR amplified genomic
DNA. Similarly, the second Finnish mutation FM2, a C->G transversion resulting in a splice-
site mutation, was first identified from RT-PCR amplified cDNA fragments. The mutation
was visualized in ethidium bromide stained agarose gels as two abnormal bands. The
fragments were purified before sequencing. Screening of the FM2 mutation in the intra-CUB
domain 6 intron was based on the loss of one of the two identified recognition sites for
restriction enzyme Dde1 visualized in an agarose gel.
4.4.8.   Determining the exon-intron structure and a putative promoter region
Identification of the exon-intron structure of the CUBN gene was initiated by long-range (LR)
PCR. LR-PCR was carried out using human DNA as template and Platinum Taq DNA
Polymerase High Fidelity enzyme (Life Technologies, USA). Direct sequencing of the inserts
of the BACs b7/b661M9, b11/b724P11, b12/b755F22, b15/b785G10, b16/b804N3 and
b17/b830K8, was also performed to identify exon-intron boundaries.
A putative promoter region was identified by direct sequencing of the inserts of two BACs,
b7/b661M9 and b11/b724P11. The sequence was analyzed for putative transcription factor
elements using the following databases at World Wide Web: Genomatix (MatInspector
professional: http://www.genomatix.gsf.de/cgi-bin/matinspector_prof/mat_fam.pl), GBF
Bio informat ics  (Mat Inspec tor  V2.2 :  h t tp : / /www.cb i l .upenn .edu/cg i -
bin/tess/Tess?_if=1&RQ=WECOME) (Quandt et al. 1995), TESS (BCM Search Launcher:
Gene Feature Searches: http://dot.imgen.bcm.tmc.edu:9331/seq-search/gene-search.html)
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and  BioInformat ics  and  Molecula r  Analys i s  Sec t ion  (BIMAS)
(http://bimas.dcrt.nih.gov/molbio/signal). Genome-wide repeats in some of the introns and in
the promoter region were identified using the National Center for Biotechnology Information
Basic Local Alignment Search Tool (NCBI BLAST: http://www.ncbi.nlm.nih.gov/BLAST/)
(Altschul et al. 1997).
4.5. Functional studies
4.5.1.   Western-blot analysis
To analyze the expression of cubilin protein, urine samples from Finnish MGA1 patients and
healthy controls were collected and immediately frozen. The urine was dialyzed against
water, lyophilized and resuspended in PBS. Concentrated urine samples were loaded on a
non-reducing 4-16% SDS-gel and electroblotted onto Immobilon PVDF membrane. As
primary and secondary antibodies a monoclonal mouse anti-human cubilin antibody (Sahali et
al. 1992) and an alkaline phosphatase labeled anti mouse IgG were used, respectively.
4.5.2.   Radioisotope binding assay
Urine specimens from 10 Finnish MGA1 patients from eight families, their healthy parents
and siblings and 13 healthy controls were collected in the morning and kept at 4°C only for a
few hours until analysis. The IF-receptor activity was measured by a radioisotope-binding
assay. In the assay, free IF-B12 complexes were separated from the IF-B12 complexes bound
to the receptor, by hydrophobic absorption of the receptor-IF-B12 complex to phenyl-
Sepharose (Guéant at al. 1995). The urine samples were incubated with CN (57Co) Cbl labeled
IF before a suspension of phenyl-Sepharose was added. The amount of measured radioactivity
corresponded to the urinary receptor activity for the labeled IF-B12 complex.
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5. RESULTS AND DISCUSSION
5.1. Genetic assignment of the MGA1 locus
5.1.1.   Linkage studies map the MGA1 locus to chromosome 10p (study I)
The 24 Finnish patients in 17 families that were accepted by Professor Ralph Gräsbeck as
MGA1 patients, in addition to the three Norwegian families, were chosen for this study.
The linkage study was initially performed with six multiplex Finnish MGA1 families. After
typing less than one hundred markers, a significant lod score value was first detected with
marker D10S191 on chromosome 10p. At this point, also the three Norwegian multiplex
families were included in the study. Additional markers were studied to confirm linkage and
the highest lod scores were obtained with two markers centromeric to D10S191, D10S1476
and D10S1477. In addition a multi-point linkage analysis between the MGA1 locus and the
seven closest marker loci localized the MGA1 gene closest to marker D10S1477 with a
maximum lod score of 5.36. The use of multi-point linkage analysis did not provide any
additional information suggesting that the marker D10S1477 and the MGA1 loci were not in
strong linkage disequilibrium, which was also demonstrated by a low Pexcess value (Pexcess
0.53). Nonetheless, as a result from one of the Norwegian families, where the younger
affected twin displayed a recombination, the gene was at this point placed more telomeric to
marker D10S466. As the following step, the additional eleven Finnish MGA1 families with a
single affected child were analyzed confirming linkage to chromosome 10p.
5.1.2.   Linkage disequilibrium and haplotype analyses (studies I, II)
After analyzing an additional number of new polymorphic markers in the region, two of them
AFM234zf10 and D10S504, showed a highly significant allelic association with MGA1 in the
Finnish families. This result further refined the region to about 4 cM and once more switched
the localization of the MGA1 gene centromeric to D10S1477. The area of strong linkage
disequilibrium was very limited implying a quite old mutation for MGA1. As a result the
younger Norwegian twin was considered not affected and her vitamin B12 treatment was
discontinued under supervision of her physician. The most likely order and distance between
the markers in the region according to the Whitehead institute/MIT Center for Genome
Research (http://www-genome.wi.mit.edu/) and our haplotype and RH data are shown in
Figure 4.
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Figure 4. The genetic map of chromosome 10p is showing the relative position of the marker loci in
the MGA1 region. Pexcess values are also indicated for some of the markers closest to the MGA1 locus.
Initially, extended haplotypes over the MGA1 region were constructed with nine markers
spanning ~14 cM between the markers D10S570 and D10S586 in the Finnish and Norwegian
multiplex families. Later more markers were studied and added to the haplotypes. By genetic
and linkage disequilibrium mapping, the critical region was limited to an interval less than 2
cM between markers D10S1476 and D10S548. The use of linkage disequilibrium has shown
to be a powerful tool for high-resolution mapping of genes in isolated populations. The
method has successfully been applied as guidance for the mapping and cloning of several
autosomal recessively inherited disease genes in the Finnish population (de la Chapelle 1993,
Hästbacka et al. 1994, Vesa et al. 1995, Höglund et al. 1996, de la Chapelle & Wright 1998,
Peltonen 2000). Later a candidate gene encoding the intrinsic factor receptor (IF-R) precursor,
cubilin was cloned by a functional approach and mapped to the same region by a Danish-
French group (Kozyraki et al. 1998). After the gene for MGA1 was identified, five novel
intragenic markers, four SNPs and a (AC)n repeat, were found when sequencing the gene and
added to the haplotypes. The region with strong allelic association associated with FM1 was
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very limited based on historical recombinations, implicating a very old Finnish mutation. This
interpretation is consistent with our haplotype data, which suggested that most of the Finnish
disease chromosomes carry the same ancestral mutation.
Table 2. Finnish haplotypes associated with the MGA1 gene.
The intragenic markers are FM2, FM1, CUB15P, CUB15IP and CUB27I(AC)n. CUB15P and
CUB15IP are SNPs in CUB domain 15 and in intra CUB15 intron. Exonic nucleotides are indicated in
capital letters and intronic nucleotides in small letters. CUB27I(AC)n is a highly polymorphic (AC)n
repeat in the last intron of the cubilin gene.
(R: observed recombination events, NA: not applicable; ND: not determined)
Table 2a
TEL Markers CEN
Mutation D10S1476 D10S504 AFM234zf10 D10S1714 D10S548
pexcess N 0.68 0.92 0.91 0.49 0.25
FM1 6 1 8 3 6 3
FM1 1 1 ND 3 6 3
FM1 1 1 8 3 R 3
FM1 5 1 8 3 6 1
FM1 3 1 8 3 8 4
FM1 3 1 8 3 14 1
FM1 3 2 8 3 6 1
FM1 1 1 8 3 3 3
FM1 1 5 8 3 3 3
FM1 1 5 8 3 7 1
FM1 1 2 8 3 8 2
FM1 1 2 8 3 8 4
FM1 1 1 9 3 5 1
FM1 1 1 4 6 6 4
FM1 1 5 8 6 2 2
FM1 1 2 ND 3 1 2
Total 31
FM2 2 2 9 3 7 2
FM3 1 3 7 6 12 1
38
Table 2b
Mutation D10S504 AFM234zf10 FM2
(CUB6)
FM1
(CUB8)
CUB15P CUB15IP CUB27I(AC)n D10S1714
pexcess N 0.92 0.91 NA NA ND ND 0.79 0.49
FM1 12 8 3 c T G a 7 6
FM1 1 ND 3 c T G a 7 6
FM1 4 8 3 c T G a 7 8
FM1 2 8 3 c T G a 7 14
FM1 1 8 3 c T G a 7 7
FM1 2 8 3 c T G a 7 3
FM1 1 9 3 c T G a 7 5
FM1 1 4 6 c T G a 7 6
FM1 1 8 6 c T G a 2 2
FM1 1 8 3 c T G c 7 14
FM1 1 8 3 c T G c 8 6
FM1 1 8 3 c T G c 8 8
FM1 1 8 3 c T C c 7 6
FM1 1 8 3 c T C c 8 6
FM1 1 ND 3 c T C c 8 1
Total 31
FM2 2 9 3 g C C c 4 7
FM3 1 7 6 c C C c 2 12
Table 3. Norwegian haplotypes associated with the MGA1 gene.
The intragenic markers are FM2, FM1, CUB15P, CUB15IP and CUB27I(AC)n. CUB15P and
CUB15IP are SNPs in CUB domain 15 and in intra CUB15 intron. Exonic nucleotides are indicated in
capital letters and intronic nucleotides in small letters. CUB27I(AC)n is a highly polymorphic (AC)n
repeat in the last intron of the cubilin gene.
(R: observed recombination events, ND: not determined)
Table 3a
Norway D10S1476 D10S504 AFM234zf10 D10S1714 D10S548
FamA 2 ND 3 7 1
FamA 2 ND 3 12 2
FamD 5 ND 6 3 R
FamC 5 ND 6 6 4
FamC 2 ND 6 8 3
FamD 5 ND 13 7 1
Table 3b
Norway D10S504 AFM234zf10 FM2 FM1 CUB15P CUB15IP CUB27I(AC)n D10S1714
FamD ND 3 c C C c 7 7
FamA ND 3 c C G c 7 12
FamC ND 6 c C C c 4 3
FamC ND 6 c C C c 4 6
FamA ND 6 c C G c 4 8
FamD ND 13 c C G c 4 7
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Differences in the disease haplotypes between the Finnish and Norwegian suggested more
than one common mutation. Our haplotype data suggested that most of the Finnish disease
chromosomes carried the same ancestral mutation, while at least two Norwegian mutations
were predicted based on their haplotypes.
5.2. Physical mapping
5.2.1.   Yeast artificial chromosome contig (study II)
Since the region displaying linkage was quite large, the use of YAC clones was the only
option to assemble a physical map for positional cloning. A YAC contig of nine YACs was
constructed over an approximately 4-cM region between the flanking markers D10S1653 and
D10S548. The adjacent and partially overlapping YACs were ordered by STS and EST
content mapping. The STS content mapping identified four overlapping segments for the
markers AFM234zf10 and D10S504 showing the highest allelic association with the MGA1
locus. The Mega YACs from CEPH ranged from 270 kb to 1780 kb in size and were all
reported to be quite chimeric except for one (YAC-12). Because of the high degree of
chimerism, the YAC contig was only used for refined mapping of new ESTs in the absence of
any obvious candidate genes in the region.
5.2.2.   Bacterial artificial chromosome contig (studies II, III)
In order to determine the genomic structure of the CUBN gene, a BAC contig was established
covering the entire gene. The BACs are usually more stable than the YACs, due e.g. to
smaller inserts, and are also very useful since they can be used for direct sequencing. The
human BAC library was initially screened using 9.4 kb of the 10.9 kb CUBN cDNA as probe.
Altogether 16 overlapping BAC clones were identified that were positive for the five
intragenic markers in the CUBN gene. The BAC contig was then screened with the closest
STS markers in the region. However, none of the BACs were positive for the STS markers
flanking the gene, indicating that the distance between the markers and the gene was quite
large.
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5.3. A candidate gene
5.3.1.   Cubilin - a functional and positional candidate gene for MGA1 (study II)
A functional candidate gene, CUBN, for MGA1 was identified by a functional approach and
mapped to the same 6-cM chromosomal region by a Danish-French research group (Kozyraki
et al. 1998) as we earlier identified by recombinant-based linkage analysis. The CUBN gene
was encoding the receptor, cubilin (previously called gp280), present in the epithelium of
intestine and kidney and the yolk sac (Moestrup et al. 1998). Previous studies had already
indicated that the 460-kDa gp280 protein may act as a receptor for the IF-B12 complex and
that gp280 and the IF- receptor in fact are identical proteins (Birn et al. 1997, Seetharam et al.
1997). The unique structure of cubilin showed a stretch of about 110 amino acids followed by
a cluster of eight epidermal growth factor repeats (EGF) and a large cluster of 27 CUB
domains (an abbreviation of Complement subcomponents Clr/Cls, Uegf and Bone
morphogenic protein-1, Bork & Beckmann 1993) and lack of a typical N-terminal
transmembrane segment. Due to the high amount of CUB domains the receptor was named
cubilin (Moestrup et al. 1998). The assembling of cubilin has been studied in the bovine
homologue, and it has been proposed that the receptor is organized into a trimer of identical
subunits (Lindblom et al. 1999).
The CUB domain structure contains two layers of five-stranded antiparallel β-sheets
connected with β-turns (Bork & Beckmann 1993, Romero et al. 1997). CUB domains are
mainly seen in a few copies in developmental proteins, such as spermadhesins, talloid protein
and bone morphogenetic protein-1 that comprise of multiple EGF and CUB binding domains
(Bork & Beckmann 1993). The cubilin structure is although unique due to the very high
number of 27 CUB domains.
Since cubilin has no classical transmembrane segment it might require a coreceptor. The
colocalizing 600-kDa transmembrane transcobalamin-vitamin B12 receptor megalin (gp330)
is suggested to carry out that function (Moestrup et al. 1996, Birn et al. 1997, Christensen et
al. 1998, Moestrup et al. 1998). No binding of the IF-B12 complex direct to megalin has been
shown (Birn et al. 1997). Megalin and cubilin are both expressed in the endocytic vesicles of
the absorptive epithelia in the intestine, kidney and yolk sac (Birn et al. 1997, Moestrup et al.
1998).
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Figure 5. Epithelial receptors important for vitamin B12 uptake into the cell.
(Picture provided by Søren K. Moestrup)
The existence of 27 CUB domains in cubilin indicates a high number of putative sites for
various protein interactions. Cubilin binds, as megalin does, the receptor-associated protein
(RAP) (Birn et al. 1997, Kristiansen et al. 1999, Birn et al. 2000) and cubilin is suggested to
play a role in the endocytosis and trafficking of immunoglobulin light chains in renal
proximal tubule cells (Batuman et al. 1998). Additional studies have shown that cubilin also
acts as a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density
lipoproteins (HDL) in the kidney (Hammad et al. 1999, Kozyraki et al. 1999).
Megalin Cubilin
cytoplasm
TC-B12
IF-B12
membrane
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Cubilin as many other CUB domain proteins also seems to play a role in embryonic
development. Previous experimental studies performed in rats have shown that antibodies
raised against cubilin induced fetal malformations including central nervous system defects
(Sahali et al. 1992). Disruption of the gene for megalin in mice also causes severe central
nervous system malformations that are associated with a decreased lipoprotein uptake in the
early neuroectoderm and visceral yolk sac (Willnow et al. 1996). Other studies support a
functionally significant association between cholesterol metabolism and the embryonic
development of the central nervous system (Herz et al. 1997).
The CUBN gene was PCR screened with an intragenic marker against the established YAC
contig and showed to be positive for the same YAC clones as the two markers, AFM234zf10
(Pexcess 0.91) and D10S504 (Pexcess 0.92), showing the strongest allelic association with
MGA1. Consequently, the putative functional candidate gene also turned out to be a strong
positional candidate gene for MGA1.
5.4. Mutation analyses
5.4.1.   Mutational analyses of the CUBN gene (study II)
To test the assumption that mutations in CUBN, encoding the IF-receptor, cause hereditary
megaloblastic anemia 1 (MGA1), RT-PCR and direct sequencing were performed with two
MGA1 patients (one Finnish and one Norwegian), one of their children (heterozygous for
MGA1) and one unrelated healthy control from both the Finnish and Norwegian population.
Additionally, a Southern-blot analysis was carried out in the Finnish and Norwegian MGA1
families to exclude a possible chromosomal misalignment of the gene due to its highly
repetitive nature.
Two different mutations in the CUBN gene were identified in the Finnish MGA1 families.
The first Finnish mutation (FM1) identified was a point mutation, a C->T transition at
nucleotide 3916 in CUB domain 8. This missense mutation causes an amino acid change from
proline to leucine (P1297L), which causes an impaired recognition of the IF-B12 complex by
cubilin (Kristiansen et al. in press). Patients from the majority of the Finnish families, 15 out
of 17, were homozygous for this mutation, whereas one family was compound heterozygous
and another was homozygous normal for FM1. In 316 control chromosomes, one FM1
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heterozygote was identified indicating a 0.003 carrier frequency, which is in accordance with
earlier estimations (Furuhjelm & Nevanlinna 1973). The proline residue is highly conserved
in multiple CUB domains in the cubilin protein both in human and rat, indicating that it is
functionally important (Bork & Beckmann 1993, Moestrup et al. 1998, Kozyraki et al. 1998).
The cubilin receptor is otherwise also quite conserved among the two species showing a 69%
identity (Kozyraki et al. 1998).
The second Finnish mutation, FM2, was a C->G transversion that resulted in a complex splice
mutation by activating a cryptic splice donor site which results in an in-frame insertion of
multiple stop codons in the intra CUB domain 6 intron. In contrast to the patients
homozygous for FM1, no cubilin protein was detected with Western blot analysis in the urine
sample from the patient homozygous for FM2. This suggested that FM2 might alter the
stability of the mutant FM2 cubilin transcript. Additional studies have also shown that the
FM2 patient had a high urinary apoA-I excretion level and an elevated fasting HDL-
cholesterol concentration. In opposite, no apoA-I was detected in the urine of the two FM1
patients studied, indicating that these patients take up apoA-I in the kidney (Kozyraki et al.
1999). The FM2 mutation was identified in only one Finnish MGA1 family where the
patient’s parents were first cousins both paternally and maternally. No carriers were observed
in either the Finnish control samples or the three Norwegian MGA1 families. Thus, it was
concluded that FM2 constitutes a private mutation that most likely is unique and occurred
relatively recently. Since one of the Finnish MGA1 was compound heterozygote for FM1, this
indicates that there has to be a third Finnish mutation, FM3. Clinically, the FM1, FM2 and
FM1/FM3 patients are not distinguishable.
Recognition of the binding site for IF-B12 to the CUB domains 5-8 in cubilin relates to the
identification of the two mutations, FM1 and FM2. The two Finnish mutations are in the same
critical region in cubilin that binds the IF-B12 complex (Kristiansen et al. 1999).
FM1 accounts for 31 of 34 (91%) disease chromosomes and constitutes the major Finnish
MGA1 mutation. For many Finnish diseases for which the molecular defect has been
identified, over 90% of disease alleles have shown to carry the same causative mutation (de la
Chapelle & Wright 1998, Peltonen et al. 1999). In spite of sequencing the entire 10.9 kb
CUBN coding region, as well as substantial portions of the intervening intronic sequence, in
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three patients and one carrier from the Norwegian multiplex MGA1 families, no mutation has
been found.
The genetic basis of selective vitamin B12 malabsorption with proteinuria has also been
studied in a canine model (giant schnauzer dogs) closely resembling the human MGA1
phenotype (Fyfe et al. 1989, Fyfe et al. 1991a). The canine CUBN gene was shown to be
highly identical with the human (83% identity) and the rat (70% identity) cubilin genes.
Linkage to the canine CUBN gene was however rejected in the canine family indicating that
the disorder resembling MGA1 is caused by a gene defect in a distinct gene product other
than cubilin (Xu et al. 1999).
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5.5. The genomic structure of the human cubilin gene (study III)
The complete genomic structure of CUBN was determined by both LR-PCR and by direct
sequencing of BAC clones that were positive for CUBN intragenic markers. The cubilin gene
consists of 67 exons and 66 introns spanning about 170 kb. The leader (L) region is
interrupted by three introns while the fourth intron is located in the junction between the
leader region and the first EGF domain. The following EGF domains are all divided by
introns except for EGF8. The next intron after the EGF repeats is located in the junction
between EGF8 and the first CUB domain. The exon-intron pattern seems to be the same in
almost every one of the following 27 CUB domains. All CUB domains are preceded by an
intron and interrupted by an internal intron, except for CUB domain 11 that is interrupted by
two internal introns (Figure 7). The size of the introns varied from 159 bp to about 11.3 kb.
Figure 7. The genomic structure of the cubilin gene showing the distribution of the 66 introns
(arrows), 3 introns in the leader (L) region, 1 intron before the first EGF repeat, 7 introns in the 8 EGF
domains, 1 intron between the last EGF domain and the first CUB domain and 54 introns in the 27
CUB domains. (Picture provided by Søren K. Moestrup and modified)
No obvious TATA box was detected in the putative promoter sequence. Instead several other
potential transcription-regulation sites, such as Sp1 binding sites, were identified. Moreover,
binding sites for other common and more tissue specific were found. In addition to a possible
CCAAT box and a CCAAT/enhancer binding protein site, the following transcription factor
elements that are both tissue restricted and tissue specific were identified: different GATA
factors, Lmo2/Tal-1/E2A complex and hepatocyte nuclear factors HNF-1 and HNF-4. The
COOH
8 EGF repeats                                            27 CUB domains     
L region
11
EGF domain CUB domain
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human megalin/LRP-2 promoter has also recently been characterized (Knutson et al. 1998).
Although cubilin and megalin are expressed in the same tissues, and presumably belong to the
same family of receptors, their promoters only partly resemble each other. Both promoters
have Sp1 binding sites, however the cubilin promoter lacks the atypical TATA element that
seems to be essential for LRP-2 promoter activity (Knutson et al. 1998).
5.6. Urinary assay of the IF-receptor (study IV)
Previous studies have identified several different cobalamin-binding proteins in urine. These
proteins include IF, haptocorrin (HC) and the IF-receptor (Gräsbeck et al. 1982, Wahlstedt &
Gräsbeck 1985, Guéant et al. 1995). The IF-receptor activity in urine is measurable and
correlates well with the receptor activity in ileal biopsies (Guéant et al. 1995, Safi et al. 1995),
where similarly decreased or absent receptor activity has been observed in MGA1 patients
(Burman et al. 1985).
In this study the receptor activity was measured in 10 Finnish MGA1 patients, 11 of their
first-degree relatives and 13 healthy control individuals. The study was performed with the
same patients used in the linkage analysis but before the cubilin gene had been cloned and the
mutations identified. The receptor activity in the urine of the MGA1 patients was extremely
low or almost undetectable compared with the healthy relatives and the controls. Similar
results have also been observed by a French research team (Guéant et al. 1995, 1999). No
distinction in receptor activity was observed between the FM2 and the FM1 patients.
Differences in receptor activity were not observed among the heterozygote carriers and the
healthy controls studied. Therefore this method might be reliable for diagnostic purposes but
it is not able to detect possible carriers for the disease.
Further studies with the same Finnish MGA1 patients showed that they excrete significantly
higher amounts of IF in the urine than the control individuals. The elevated values of IF in the
urine may be caused by the absence of a functional IF-receptor in the kidney (Dugué et al.
1999). Patients from Kuwait have also been tested for receptor activity in urine but did not, in
contrast to the Finnish patients, show any decrease of receptor activity and actually in one
family there was increased excretion (Gräsbeck 1997, Dugué et al. 1999). Increased amounts
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of an unstable IF-receptor detected in ileal biopsy specimens, has also been reported (Eaton et
al. 1998).
5.7. Genealogical studies (unpublished data)
The MGA1 disease gene is predominantly clustered in the south-central and eastern parts of
Finland. The distributions of the birthplaces for the grandparents of the MGA1 patients’
participating in this study are shown in Figure 8. These two regions were settled in two
expansions during the early settlement (old Finland) in which the population began to expand
some 2,000-2,500 years ago and late settlement (new Finland) in which population expansion
started mainly approximately 500 years ago in the 1500’s (Norio et al. 1973). The presence of
the MGA1 gene in both the old and new Finland indicates that the mutation is of a relatively
old origin. In cases of autosomal recessive disorders where the mutations are geographically
widespread, the founding has occurred a long time ago (de la Chapelle 1993). The major
Finnish mutation FM1, most likely carried by the original settlers, is mainly seen in the parts
of Finland that were inhabited later (new Finland) as a result of internal migration. In contrast
to FM1, the two minor Finnish mutations FM2 and FM3 are observed in the old part of
Finland along the coastline. These mutations may either have arisen from private mutations or
arrived with new immigrants.
The church records have served as a population register for the majority of the population for
about the last 10 generations (Norio et al. 1973) and made it possible to investigate for
consanguinity between the MGA1 families. In an earlier genealogic study performed by
Furuhjelm and Nevanlinna, 24% remotely consanguineous marriages between parents of
MGA1 patients were identified (Furuhjelm & Nevanlinna 1973).
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Figure 8. Geographic distribution of birthplaces for the MGA1 patients’ grandparents.
Filled circles and squares indicate FM1 and FM2 grandparents, respectively. The grandparents
for the postulated third mutation (FM3) are also indicated (open circles).
FM1
FM2
FM3
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6. CONCLUDING REMARKS
At the beginning of this study the molecular background of MGA1 was not known, although
evidence had been presented for the existence of an abnormal or a total lack of the intestinal
receptor for the intrinsic factor-vitamin B12 complex. More than 30 years had passed since
the disease was first described and the lack of new patients had even lead to speculations that
the disease does not exist at all or that it does not show Mendelian inheritance. This study
describes the identification of the Finnish MGA1 patients, genetic and physical mapping of
the MGA1 gene and identification of the mutations causing MGA1.
The MGA1 locus was mapped by genetic linkage analysis to chromosome 10p in Finnish and
Norwegian MGA1 families. A very strong candidate gene for MGA1, the one encoding the
IF- receptor, cubilin, was cloned by a Danish-French research team and mapped to the MGA1
region. Two mutations were identified in the MGA1 gene in the Finnish population. The
mutations include one missense mutation (FM1: P1297L) and one complex splice mutation
(FM2). One of the MGA1 patients was compound heterozygote for FM1 suggesting a third
Finnish mutation (FM3). However, no mutations were identified in the cubilin gene in the
Norwegian MGA1 patients. Based on the mutation analysis of the cubilin gene in the Finnish
and Norwegian patients it seems very possible that the same phenotype may result from one
of several genetic errors. The Norwegian patients may have mutations in the promoter region
which has not yet been analyzed, in some of the introns or in an another gene encoding a
protein that is involved in the intracellular transport of vitamin B12 and is located in the near
vicinity of the MGA1 gene. The presence of different haplotypes in the three Norwegian
MGA1 families supports the hypothesis that another gene might be involved, although the
Norwegian patients show linkage to the MGA1 locus and there is no evidence of an additional
gene. Because of the complicated multistep nature of vitamin B12 absorption from the lumen
of the intestine to the blood, genetic diversity in the disease pattern may very likely occur. All
the steps involved in the transference of vitamin B12 across the enterocytes in the ileum are
not completely understood and it is therefore very possible that more than one gene defect
may cause MGA1.
The disease has also been frequently diagnosed in Turkey and several Arabian countries
(Yetgin et al. 1983, Abdelaal & Ahmed 1991, Altay et al. 1995, Ismail et al. 1997). Those
who studied the Saudi Arabian and Kuwaiti cases suggested an X-linked mode of inheritance
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because of the abundance of affected males (Abdelaal & Ahmed 1991, Ismail et al. 1997).
Considering the multistep nature of vitamin B12 absorption, heterogeneity in the genetic basis
of the disease with a possible presence of an X-linked form would not be unexpected in the
Arabian families (Ismail et al. 1997). A difference in penetrance between the Scandinavians
and the Arabians may be another explanation why only males are affected, since in both
materials the birth rate seems to be equal in males and females. Genetic heterogeneity may in
part explain this syndrome. The differences in the expression levels of the IF-receptor in
different populations support this assumption. While a decreased IF-receptor activity was
observed in the urine from the Finnish MGA1 patients, no decrease and even a significant
increase (in one family) of the urinary receptor activity was detected in the patients from
Kuwait (Dugué et al. 1999). Overexpression of an unstable IF-receptor has also been detected
in ileal biopsy specimens from two sisters suffering from MGA1 (Eaton et al. 1998).
Although the Finnish MGA1 mutations have been identified, the question still remains why
almost no new patients have been diagnosed since the 1970’s and 1980's in Finland and
Norway. In contrast to the Arabian patients, where differences in the penetrance may occur,
no evidence of nonpenetrance was observed among the Finnish and Norwegian families
studied. In the Finnish MGA1 families none of the parents or the healthy siblings were
homozygous for either the FM1 or the FM2 mutation thereby excluding nonpenetrance in
these families. In the Norwegian families, on the other hand, where no mutation has been
identified, nonpenetrance was excluded based on the haplotype analysis alone where none of
the healthy relatives studied were homozygous for the affected haplotypes.
One explanation why the disease has “disappeared” may be a drop in the gene frequency due
to migration to the bigger cities from isolated subpopulations, where most of the MGA1
patients originate. In the cities the gene frequencies would be lower due to a dilution of genes
and homozygosity becomes very rare. In the rural high-incidence MGA1 areas in the
northeastern parts of Finland the number of births has significantly dropped since the 1950’s
to present. In the eastern parts of Finland the numbers have dropped considerably from 19,610
to 8,754 births per year (~55%) between 1950 and 1970, while the decline of births in the
whole country during that time was ~66% (from 98,065 to 64,559 births per year). Today
little more than 6,000 children are born per year in eastern Finland and about 57,000 in the
whole country. In the northeastern part of Finland, Kainuu-Kajanaland, which is a sparsely
populated high-incidence MGA1 region, the number of births has decreased as well. While
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the drop of births in the whole Finland was about 42% between 1950 and 1998, the number of
births in Kainuu-Kajanaland dropped from 2,043 births per year to 873 births per year, (a 57%
decline), during the same time period. During the corresponding time from the 1950s to today
the number of births in southern Finland have, on the other hand, increased about 25% from
12,503 to 15,551 births per year (Official Statistics of Finland 1997, 1999). A decrease in the
number of births in the rural high-incidence MGA1 areas could partly explain a decline in the
number of new patients but not the present absence of patients. Another explanation would be
that possible new patients suffering from megaloblastic anemia are treated with vitamin B12
without further examinations, which seems unlikely. As a result of the identification of the
Finnish mutations, patients suffering from megaloblastic anemia can now relatively easily be
tested for MGA1.
Drastic changes in environmental factors like the dietary habits among Finns and Norwegians
during the last fifty years might have influenced the penetrance of the gene. This hypothesis
could principally be very easily tested by population studies where healthy homozygotes for a
MGA1 mutation should be found. However, a population study can be quite difficult to
accomplish in practice since the amount of individuals studied has to be quite large due to the
low frequency of the gene in both the Finnish and the Norwegian populations.
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